U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07428616) titled 'A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma' on Feb. 19.
Brief Summary: The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Meningioma
Intervention:
DRUG: Zanzalintinib
Administered as specified in the treatment arm.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Exelixis
Published by HT Digital Content Services with permission from Health Daily Digest....